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SUMMARY 
Embryonal tumors with multilayered rosettes (ETMRs) are highly lethal infant brain cancers with characteristic 
amplification of Chr19q13.41 miRNA cluster (C19MC) and enrichment of pluripotency factor LIN28A. Here we 
investigated C19MC oncogenic mechanisms and discovered a C19MC-LIN28A-MYCN circuit fueled by 
multiple complex regulatory loops including an MYCN core transcriptional network and super-enhancers 
resulting from long-range MYCN DNA interactions and C19MC gene fusions. Our data show that this powerful 
oncogenic circuit, which entraps an early neural lineage network, is potently abrogated by bromodomain 
inhibitor JQ1, leading to ETMR cell death. 
INTRODUCTION molecular and histologic spectrum of diseases that include 
medulloblastoma, rhabdoid tumors, and a more recently discov- 
Embryonal brain tumors, the largest category of malignant brain ered tumor entity, embryonal tumors with multilayered rosettes 
tumors diagnosed in children 0–14 years of age, comprise a (ETMRs), which were first identified based on recurrent 
Significance 
ETMRs are distinctly challenging brain tumors of infants and very young children, with characteristic rapid progression and 
only 10%–20% overall survival. Since the discovery of C19MC, an embryonic stem cell-enriched, primate-specific miRNA 
cluster, as a disease marker of ETMR, there has been limited progress in biological and therapeutic understanding of this 
disease. Here we show that tumor-specific genomic and epigenomic alterations of C19MC entraps and drives multiple 
feedforward loops to fuel a potent C19MC-LIN28A-MYCN oncogenic circuit, which can be powerfully abrogated by bromo-
domain inhibitors. Our findings underscore C19MC as a critical oncogene in ETMRs and provide critical therapeutic insights 
and a framework for developing high-fidelity models for this orphan 
disease. Cancer Cell 36, 51–67, July 8, 2019 ª 2019 Elsevier Inc. 51 
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amplification of the C19MC miRNA cluster on Chr19q13.41 (Li 
et al., 2009). Subsequent studies revealed a spectrum of 
embryonal brain tumors previously categorized as distinct 
histologic entities that exhibited overlapping molecular features, 
which led to the categorization of C19MC-altered embryonal 
tumors as a single diagnostic entity in the revised 2016 World 
Health Organization CNS tumor classification (Louis et al., 
2016). ETMRs are now increasingly recognized as a distinctly 
aggressive brain tumor arising in infants and young children <4 
years old with long-term survival of only 10%–20% (Korshunov 
et al., 2014; Li et al., 2009; Spence et al., 2014b). To date, 
biological and therapeutic studies of this orphan disease has 
been significantly limited by a paucity of experimental and 
therapeutic models. 
C19MC, which is the largest primate-specific miRNA cluster, 
encodes 54 miRNAs normally expressed in placental and 
germinal tissues (Bentwich et al., 2005; Bortolin-Cavaille et al., 
2009). ETMRs exhibit histologic features reminiscent of early 
neural tube development and are transcriptionally enriched for 
genes with functions in early neural differentiation, including 
LIN28A, POU3F2, MEIS1/2, and SOX3 (Li et al., 2009; Pfister 
52 Cancer Cell 36, 51–67, July 8, 2019 
et al., 2009; Picard et al., 2012), suggesting early neural progen-
itor origins. Significantly, ETMR RNA sequencing (RNA-seq) 
studies revealed fusion of C19MC to the promoter of TTYH1 (an 
embryonic chloride channel protein), and correlated C19MC 
miRNA expression with enrichment of an early neural-restricted 
isoform of the de novo DNA methyltransferase, DNMT3B6 
(Kleinman et al., 2014). These observations, along with our 
previous demonstration that C19MC oncogenic miR-NAs 
(oncomiRs) modulates human neural stem cell (hNSC) growth 
and differentiation (Li et al., 2009), suggests that C19MC may 
promote or maintain a primitive neural/embryonic epigenetic cell 
phenotype in ETMRs. However, oncogenic mechanisms and 
gene targets of C19MC remain elusive. 
ETMR transcriptional signatures are enriched for high expres-
sion of LIN28A, a pluripotency factor and RNA-binding protein, 
which is implicated in neural development and in the pathogenesis 
of other advanced cancers (Viswanathan et al., 2009). Notably, 
LIN28A is highly expressed in a small proportion of embryonal 
tumors with transcriptional and epigenetic features of ETMRs 
without evident C19MC alterations or expression, indicating an 
important role for this oncogene in ETMR pathogenesis 
 
 
Figure 1. Global Molecular Features of ETMRs 
(A) t-SNE visualization of unsupervised cluster analyses of 850k Illumina methylation array data from ETMRs (n = 80) and a reference dataset of childhood 
brain tumors and neuroblastoma (n = 643). 
(B) Circos plot of global methylation-based copy-number profiles in ETMRs. Regions of amplification/gains and losses are respectively highlighted in red and 
green. 
(C) High-resolution SNP copy-number profiles generated using allele-specific copy-number analysis of tumors in a representative ETMR with focal 
Chr19q13.42 amplification encompassing C19MC (red) and TTYH1 (blue) shown in zoomed-in view. 
(D) Heatmap of NanoString (v.3) miRNA expression data from 21 ETMRs and 28 other PBTs showing the top 20% of miRNAs enriched in ETMRs; *q < 0.05. 
FDR, false discovery rate. See also Figure S1 and Table S1. 
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Figure 2. C19MC oncomiRs Cooperatively Target Multiple Cell-Cycle Tumor Suppressors 
(A) Cell viability assays of A664-5miR, hNSC6-5miR, hNSC6-miR520g, and control cell lines 5 days post-seeding. 
(B) Cell-cycle analysis of hNSC6-5miR, hNSC6-miR520g, and control cell lines 5 days post-seeding; proportion of cells relative to total cell numbers are shown. 
(C) Schema of integrated differential RNA-seq analyses comparing hNSC6-5miR versus vector control cell lines (n = 2) and primary ETMRs (n = 22) versus 
other PBTs (n = 17); number of significantly up-, downregulated, and common C19MC responsive genes (FC > 1.2, <-1.2; *q < 0.05) are shown. Heatmap 
shows relative expression of select genes from the most highly ranked biological processes in ETMRs versus other PBTs identified using pathway analyses of 
4,192 C19MC responsive genes; *q < 0.05. 
(D) Cytoscape visualization of biological processes (*q < 0.05) represented by the 4,192 genes identified in (C). Nodes represent related enriched 
gene sets, node size corresponds to total gene numbers. 
(E) qRT-PCR and western blot analyses of hNSC6, Daoy, UW228, and A664 cell lines with miR520g and 5miR expression, is shown relative to 
corresponding vector control lines. 
(legend continued on next page) 
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(Korshunov et al., 2014; Spence et al., 2014b). In this study, we 
sought to define downstream targets and oncogenic mecha-
nisms of C19MC, and to elucidate the functional relationship of 
C19MC and LIN28A in ETMR transformation. 
RESULTS 
Recurrent Chromosome 2 and 19 Copy-Number 
Alterations Are Hallmarks of ETMRs 
The molecular landscape and pathogenesis of ETMRs remain 
largely unknown, as few of these tumor entities have been 
extensively characterized. To begin to elucidate mechanisms of 
ETMR pathogenesis, we examined 80 primary ETMRs using 
integrated global methylation, SNP, transcriptional, and miRNA 
profiling (Table S1). Methylation and transcriptional profiling 
showed ETMRs are distinct from other pediatric brain tumors 
(PBTs), notably embryonal brain tumors, including rhabdoid 
tumors, pineoblastoma and medulloblastoma (Louis et al., 2016) 
(Figure 1A). Transcriptional analyses confirmed characteristic 
enrichment of stem cell maintenance and early 
neural/embryonic developmental pathways in ETMRs. Copy-
number analyses using methylation and Omni SNP array data 
showed that Chr2 gains (77.5%) and focal Chr19 alterations 
(80%) centered on C19MC were the most frequent copy-number 
aberrations (CNA) and were concurrently present in 65% of 
ETMRs (Figures 1B and S1A–S1C). Detailed methylation/SNP 
(n = 80) and RNA-seq (n = 22) analyses confirmed that C19MC 
was recurrently targeted by amplification/copy-number gains 
and fusions with TTYH1 (Figure 1C). Consistently, profiling of 
565 miRNAs using NanoString analyses (Figure 1D; Table S1) 
showed that C19MC oncomiRs, and not the syntenic miR371-
373 cluster (Li et al., 2009), were exclusively upregulated in 
ETMRs, while expression of miR-15 and the let-7 tumor 
suppressor miRNAs were downregulated in ETMRs relative to 
other PBTs. Interestingly, the embryonic stem cell (ESC)-
enriched 17–92 oncomiR cluster implicated in medulloblastoma 
(Murphy et al., 2013), was upregulated in other PBTs, but only 
modestly expressed in ETMRs, underscoring a very specific 
causative role for C19MC oncomiRs in ETMRs. 
C19MC oncomiRs Cooperatively Target Multiple Cell-
Cycle Tumor Suppressors 
We previously showed that individual C19MC miRNAs, miR520g 
and miR517c, can promote in vitro and in vivo transformation (Li 
et al., 2009); however, the collective effect of C19MC oncomiRs 
and the nature of common C19MC target genes in ETMRs have 
not been examined. To elucidate C19MC oncogenic mecha-
nisms, we investigated the effect of a maxi-gene containing five 
C19MC miRNAs (5miR) (Figures S2A and S2B) most highly 
expressed in primary ETMRs (Li et al., 2009), on growth of 
A664—a cell line derived from a primary ETMR (Figures S2C– 
S2F) and hNSC6, an hNSC line. Stable 5miR expression 
enhanced both A664 and hNSC6 cell viability and accelerated 
G1/S transition in hNSC6, while miR520g expression had limited 
effects on hNSC6 growth (Figures 2A and 2B). These observa-
tions indicated that multiple C19MC oncomiRs may act cooper-
atively on gene targets to promote ETMR transformation. 
To identify C19MC oncomiR targets relevant to primary ETMR 
biology, we first performed comparative RNA-seq analyses of 
hNSC6-5miR and corresponding vector controls to identify 
C19MC responsive genes and then integrated these data with 
differential RNA-seq analyses of ETMRs versus other PBTs to 
identify C19MC targets or effectors specifically enriched in ETMRs 
(detailed in Table S2). Differential analyses of hNSC6-5miRs 
versus control lines revealed 12,729 C19MC responsive genes 
(6,305 up- and 6,424 downregulated genes; n = 2; false discovery 
rate [FDR] < 0.05; fold change [FC] > 1.2, <-1.2), while analyses 
of primary ETMRs (n = 22) and other PBTs (n = 17) revealed 
6,002 enriched genes (FDR < 0.05; FC > 1.2, <-1.2). Integration of 
the two datasets identified 4,192 common genes, of which 2,044 
and 2,148 were, respectively, up- and downregu-lated in both 
hNSC6-5miR cells and ETMRs. Functional enrichment analyses 
of the 4,192 C19MC responsive genes revealed neural stem cell 
maintenance, epigenetic regulation, and miRNA processing genes 
as C19MC upregulated targets, while apoptosis, mRNA stability, 
and neurogenesis genes comprised C19MC downregulated 
targets (Figures 2C and 2D; Table S2). 
In keeping with the rapidly proliferative nature of ETMRs and 
accelerated cell-cycle phenotypes in hNSC6-5miR cells, genes 
involved in cell-cycle regulation comprised one of the largest 
C19MC responsive hubs (12.5%; p = 1.32 3 10-22; 347 up-and 179 
downregulated genes). As miRNAs predominantly negatively 
regulate gene expression, we focused on the 3' UTR sequences 
of the 179 downregulated cycle-cell genes to identify C19MC 
binding sites, using strict criteria detailed in methods. These 
analyses revealed that only 11/179 C19MC downregu-lated genes 
harbored multiple evolutionarily conserved C19MC miRNA 
binding sites in their 3' UTRs (Table S2). We applied H3K27Ac 
chromatin immunoprecipitation sequencing (ChIP-seq) and assay 
for transposase-accessible chromatin using sequencing (ATAC-
seq) data available for 5 ETMRs to assess the functional status of 
these loci in primary tumors and observed that only 5/11 loci, 
including AHR, CCND2, CDKN1A (p21), CDKN1B (p27), and 
RBL2, exhibited both active enhancer marks and open chromatin 
in a majority (>3/5) of ETMRs (Table S2). Our analyses did not 
identify MYC or MAX, pRB pathway tumor suppressor genes 
(CDKN2A/B, CDKN2C, and RB1), TP53 or PTEN, which are 
frequently implicated in other brain tumors, 
(F) Summary of luciferase reporter assays in UW228 cells co-transfected with combinations of empty vector or miR520g/5miR expression plasmids, and wild-
type (WT), mutated p21, or p27 3' UTR reporter constructs; 3' UTR 520g-t constructs served as miRNA target binding control. Luciferase activity was normalized 
to Renilla and vector control. 
(G) High-magnification image of miRNA in situ hybridization (ISH) and immuno-histochemical (IHC) analyses performed on sequential tissue sections of 
primary ETMR using fluorescence-labeled miR520g and scrambled control (scr) probes, and anti-p21, p27, and RBL2 antibodies. Scale bars, 100 mm. miRNA 
expression and tumor nuclei are respectively visualized in green and blue; corresponding regions in inset lower-magnification images are indicated by arrows. 
Scale bars, 20 mm. 
Ctrl indicates controls; data are presented as means ± SEM (n = 3); significance was determined by unpaired two-tailed Student’s t test; *p < 0.05; mRNA 
expression is normalized to actin and tubulin served as western blot loading controls. 
See also Figure S2 and Table S2. 
Cancer Cell 36, 51–67, July 8, 2019 55 
 
 
A 
D 
kDa 
27 
32 
60 
50 
50 
100 
75 
50 
2 
1 
0 
B C 
 Ctrl 5miR Ctrl LIN28AsiRNA 
siRNA + 
Ctrl miR520g 5miR 2.0 40 kDa 1.5 
LIN28A 
LIN28B 
27 kDa 
 R
e
la
tiv
e
 e
xp
re
ss
io
n
 
R
e
la
tiv
e
 e
xp
re
ss
io
n
 
R
el
at
iv
e 
ex
pr
es
si
on
 LIN28A 
LIN28B 
ns LIN28A 
LIN28B 
27 20 32 1.5 ns ns 
1.0 ns MYCN 60 5 32 
1.0 MYC 50 MYCN MYCN 60 142 SALL4 0.5 2.5 ns ns ns 80 MYC 
MYC 
Tubulin 
ns 
ns 
0.5 ns ns 50 
SOX2 
Tubulin 
35 
Tubulin 50 50 0 0 0 
E F G H 
C
trl 
m
iR
52
0g
 
5m
iR
 Ctrl miR520g 5miR Amp Gain ETMR Other PBTs Ctrl LIN28A 1.5 ns 2000 
R
e
la
tiv
e
 lu
ci
fe
ra
se
 a
ct
iv
ity
 
250 
1.5 kDa 
T
T
P
 e
xp
re
ss
io
n 
1000 1000 ns ns 
LIN28A 
LIN28B 
200 27 1.0 40 1.0 
R
el
at
iv
e 
ex
pr
es
si
on
 
ns 
FP
KM
 
FP
KM
 32 150 5.0 30 0.5 
MYCN 60 
100 0.5 20 ns 0 MYC 50 2.5 kDa ns ns 
50 37 10 TTP ns Tubulin 50 
50 0 // // 0 // // // 0 0 Tubulin 
I J K NCCIT A664 hNSC6 
Ctrl TTP Ctrl LIN28A siRNA Ctrl LIN28A Ctrl 5miR 
R
el
at
iv
e 
ex
pr
es
si
on
 
 kDa 
R
el
at
iv
e 
ex
pr
es
si
on
 
R
el
at
iv
e 
ex
pr
es
si
on
 
R
 
2.0 
1.5 
LIN28A 27 1.5 1000 
ns ns 
 
1.0 1.0 37 1.0 TTP 
0.5 0.5 
50 Tubulin 
// 0 // 0 / 0 
kDa  NCCIT A664 hNSC6 C19MC 
TTP 37 
 
LIN28A 
siRNA +
 +
 kDa 
 
 
27 LIN28A 
LIN28A 
TTP 
27 
37 
50 
TTP 
60 MYCN 
32 LIN28B 
LIN28A MYCN 
Tubulin MYC 50 
Tubulin 50 
Figure 3. C19MC-LIN28A-MYCN Comprise an Oncogenic Circuit 
(A) qRT-PCR and western blot analyses of predicted C19MC targets and other neural developmental genes in stable hNSC6-miR520g, hNSC6-5miR, and 
control cell lines. NCCIT lysates served as antibody control. 
(B and C) qRT-PCR and western blot analyses of A664-5miR (B) or vector control cell lines (C) transfected with LIN28A or control siRNA. 
(D) qRT-PCR and western blot analyses of hNSC6-LIN28A or vector control lines. 
(E) RNA-seq FPKM expression values for LIN28A/B and MYC/N in ETMRs with C19MC amplification (n = 13) or copy-number gains (n = 4); *q < 0.05. Data 
are presented as individual samples, with means ± SEM indicated. 
(F) RNA-seq FPKM expression values for RNA-binding proteins predicted to target LIN28A and MYCN 30 UTR in ETMR (n = 22) and other PBTs (n = 17); *q < 
0.05. Data are presented as individual samples, with means ± SEM indicated. 
(G) qRT-PCR and western blot analyses of hNSC6-miR520g, hNSC6-5miR, and control cell lines. 
(H) Summary of luciferase reporter assays in UW228 cells co-transfected with empty vector, miR520g, 5miR expression constructs, and reporter constructs of 
wild-type (WT) or TTP 30 UTR with mutant C19MC binding sites; 520g-t constructs served as miRNA target binding control. Luciferase activity is normalized to 
Renilla and vector control. 
(I) qRT-PCR and western blot analysis of A664 cells transfected with control or TTP expression construct. 
(legend continued on next page) 
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as C19MC targets. Notably, CDKN2A/2B, which were signifi-
cantly downregulated in ETMRs (Figure 2C), lacked H3K27Ac 
marks and/or open chromatin in a majority of tumors, indicating 
that they were predominantly transcriptionally regulated. 
As AHR and CCND2 have variably reported tumor suppressor 
activity, we focused on validating canonical cell-cycle tumor 
suppressors p21, p27, and RBL2 as direct C19MC targets (Figure 
S2G). Consistent with cooperative effects of C19MC onco-miRs 
on gene targets, p21, p27, and RBL2 mRNA and protein were 
diminished by up to 2-fold in stable A664 and hNSC6 cell lines 
expressing 5miRs versus miR520g, and C19MC-mediated 
repression was conserved across different brain tumor cell lines 
(Daoy, UW228, PFSK) (Figures 2E and S2H–S2J). Importantly, 
expression of p14/16, RB1, TP53, and PTEN were unchanged in 
response to 5miR and anti-miR-mediated targeting of endogenous 
C19MC 5 miRs in ETMR2373—a C19MC amplified cell line, also 
rescued expressions of p21, p27, and RBL2, without effects on 
other cell-cycle regulators (Figures S2E, S2F, and S2K). Direct 
gene targeting by C19MC was confirmed using 3' UTR luciferase 
promoter assays, which showed that 5miR mediated significantly 
greater inhibition of p21 and p27 3' UTR activity than miR520g in 
UW228 cells, while repressive effects of both miR520g and 5miR 
were abrogated by mutations to C19MC binding sites on p21 and 
p27 3' UTRs (Figures 2F and S2L). Im-muno-histochemical and 
miRNA in situ hybridization analyses confirmed that p21, p27, and 
RBL2 protein were absent in tumor cells with high C19MC 
oncomiR expression (Figure 2G), thus confirming these multiple 
cell-cycle tumor suppressors as relevant and direct targets of 
C19MC oncomiRs in primary ETMRs. 
C19MC-LIN28A-MYCN Comprise a Feedforward 
Oncogenic Circuit 
As ETMRs exhibit few other regions of focal copy-number alter-
ations, we reasoned that C19MC may also drive ETMR growth 
via upregulation of oncogenes. Indeed, multiple oncogenes with 
functions in stem cell maintenance and neurogenesis were 
represented in the top 1% of the 2,044 genes (FDR = 7.58 3 10-
5) commonly upregulated in hNSC6-5miR and ETMRs (Figures 
2C and 2D). H3K27Ac ChIP-seq and ATAC-seq analyses 
revealed that 17 of the top 20 enriched genes, which included 
MYCN and LIN28A, exhibited active enhancer markers and 
open chromatin in a majority (3–5) of primary ETMRs (Table 
S2). Western blot and qRT-PCR analyses showed that MYCN 
and LIN28A, but not the closely related MYC and LIN28B loci, 
were upregulated in hNSC6-5miR, while only MYCN was upre-
gulated in hNSC6-miR520g cells (Figures 3A and S3A). Other 
genes enriched in ETMRs, including SALL4, CRABP1, SOX2/3, 
PROM1, and POU3F2, showed inconsistent or no changes with 
5miR or miR520g expression. These findings, which suggested 
that MYCN and LIN28A were specific targets of C19MC, was 
further confirmed by analyses of stable A664-5miR cell lines 
(Figures 3B and S3A). As reciprocal LIN28B and 
MYCN regulation is observed in neuroblastoma, a pediatric 
peripheral nervous system tumor (Powers et al., 2016), we 
investigated the possibility of a C19MC-LIN28A-MYCN 
regulatory circuit. Indeed, LIN28A knockdown in A664 and 
LIN28A expression in hNSC6 cells respectively resulted in up- 
and downregulation of MYCN, while MYC was unchanged 
(Figures 3C, 3D, and S3A). Notably, we also observed that 
LIN28A and MYCN, but not LIN28B and MYC levels, correlated 
quantitatively with C19MC copy-number gains and amplification 
in primary tumors (Figure 3E), indicating that C19MC oncomiRs 
act cooperatively and specifically to drive the LIN28A-MYCN 
regulatory loop in ETMR. 
To investigate C19MC-mediated regulation of LIN28A and 
MYCN, we examined the 3' UTRs of both oncogenes for potential 
target sequences of AU-rich element RNA-binding proteins (ARE-
RBP), which function in mRNA decay. These analyses revealed 24 
and 31 candidate ARE-RBPs, respectively, for LIN28A and MYCN; 
3 of 5 ARE-RBPs predicted to target both oncogenes (TTP, 
KHSRP, hnRNPA1, and ELAVL1/2) harbored C19MC binding sites 
at 3' UTRs (Figures S3B and S3C; Table S3). Of these, only TTP 
(Tristetraprolin) was significantly downregulated in ETMR relative 
to other PBTs (Figure 3F), indicating that C19MC may act via TTP 
repression to upregulate LIN28A and MYCN. Indeed, stable 5miR 
expression robustly downregulated TTP in hNSC6 cells (Figures 
3G and S3D), while mutation of C19MC binding sites on TTP 3' 
UTR rescued 5miR-mediated repression of TTP in luciferase 
reporter assays (Figures 3H and S3E). Furthermore, transient TTP 
expression in A664 cells led to diminished LIN28A and MYCN, but 
not LIN28B and MYC expression (Figures 3I and S3D). 
Interestingly, we observed that TTP was also upregu-lated with 
LIN28A knockdown in A664 as well as NCCIT, a germ cell tumor 
line with high endogenous LIN28A, and diminished in stable 
hNSC6-LIN28A cell lines, thus indicating that TTP also maps 
downstream of LIN28A. Consistently, TTP was downregu-lated in 
A664-5miR cells, which have high LIN28A expression (Figures 3J, 
3K, and S3D). Our aggregate findings suggest that multiple 
feedback loops drive a C19MC-LIN28A-MYCN onco-genic circuit 
in ETMRs. 
LIN28A Modulates Epigenetic Effectors in ETMRs 
The discovery of a C19MC-LIN28A-MYCN circuit together with 
high LIN28A expression in ETMRs implies a significant onco-
genic role for LIN28A. Indeed, we observed that LIN28A expres-
sion and knockdown, respectively, enhanced and diminished 
viability of hNSC6 and A664 cells (Figures 4A and 4B). To inves-
tigate LIN28A oncogenic mechanisms and map ETMR-specific 
LIN28A targets, we performed and compared RNA-immunopre-
cipitation (RIP) coupled with RNA-seq analysis of A664 cells with 
RNA-seq profiles of A664 and primary ETMRs. Consistent with 
LIN28A functions in mRNA binding and stabilization (Wilbert et al., 
2012), the largest category of LIN28A targets (49.4%) mapped to 
exonic and 3' UTR sequences (Figure S4A). RIP 
(J) qRT-PCR and western blot analysis of NCCIT, A664 cells treated with LIN28A, or control siRNA and hNSC6-LIN28A stable cell lines. 
(K) qRT-PCR and western blot analysis of stable A664-5miR and control cell lines. Schema shows C19MC-mediated regulation of LIN28A/MYCN via TTP in-
hibition. Validated and predicted regulation are shown by solid and dashed lines, respectively. 
In all cell line experiments, Ctrl indicates controls, data are presented as means ± SEM (n = 3); significance was determined by unpaired two-tailed Student’s t 
test; *p < 0.05; mRNA expression is normalized to actin and tubulin served as western blot loading controls. 
See also Figure S3 and Table S3. 
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Figure 4. LIN28A Modulates Epigenetic Effectors in ETMR 
(A) Cell viability assays for stable hNSC6-LIN28A and corresponding vector control cell lines. 
(B) Cell viability assays for A664 cell line treated with LIN28A or control siRNA. 
(C) Schema for LIN28A target identification in RIP analyses of A664 cells. Green and purple circles, respectively, correspond to all genes expressed 
in A664 cells (FPKM > 1) and unique LIN28A-bound genes in A664 cells; blue circle corresponds to all genes significantly upregulated in ETMRs 
versus PBTs (q < 0.05). 
(D) qRT-PCR validation analyses of A664 LIN28A RIP and control immunoglobulin G (IgG) IP samples for known LIN28A targets and non-enriched 
genes; data are normalized to RIP input control. 
(E) Cystoscape visualization of gene set enrichment analysis of 805 LIN28A-bound genes. Percentage and number of genes in each biological 
process are shown. 
(F) RNA-seq FPKM values for DNMT3A and DNMT3B isoforms in primary ETMR (n = 22) and other PBTs (n = 17); *q < 0.05. Data are presented as 
individual samples, with means ± SEM indicated. 
(G) qRT-PCR analysis of A664 RIP and control IgG IP samples. Data are normalized to input control. 
(legend continued on next page) 
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sequencing analyses identified 38,405 LIN28A binding sites (>2-
fold enrichment; p < 0.05) corresponding to 7,146 unique target 
genes of which 805 were commonly enriched in A664 cells and 
ETMRs (Figure 4C). Specificity of LIN28A RIP was confirmed by 
qRT-PCR analyses of known LIN28A targets (CCNB1, LIN28A, 
and IGF2BP2/3) (Peng et al., 2011; Wilbert et al., 2012), and 
unrelated genes (TUBB3 and RPLPO) (Figure 4D). Consistent 
with our previous work, functional enrichment analyses showed a 
substantial proportion of LIN28A targets mapped to cell growth, 
survival, and metabolism pathways (Figure 4E; Table S4). 
Strikingly, epigenetic regulators including miRNA processing 
gene, DICER1 and de novo DNA methyltrans-ferases 
(DNMT3A/3B), which exist in multiple isoforms during embryonic 
and fetal development, comprised the largest category (14.4%; 
116/805 genes) of LIN28A-regulated transcripts enriched in 
ETMRs (Figure S4B). Although, LIN28A binding sites mapped to 
common 30 UTRs of DNMT3A and DNMT3B invariant exons 
16/17, RNA-seq analyses indicated that DNMT3A2 and the 
enzymatically active DNMT3B6 isoform were most highly en-
riched in ETMRs relative to other PBTs (Figures 4F and S4C– 
S4E). Consistently, RIP qRT-PCR analyses showed LIN28A 
binding and enrichment of DICER1, DNMT3A2, and DNMT3B6, 
but not DNMT1, in A664 cells (Figure 4G), and that LIN28A 
knockdown diminished DNMT3A2, DNMT3B6, and DICER1 
mRNA and protein expression, but had no effects on LIN28B and 
DNMT1 in A664 and NCCIT cells. Significantly, while 
DNMT3A2/3B6 and DICER1 mRNA and protein were also specif-
ically upregulated in A664-5miR cells (Figures 4H, 4I, and S4F), 
treatment of ETMR2373 with anti-miRs targeting five C19MC 
miRs only resulted in downregulation of MYCN, LIN28A, and 
DNMT3A2/3B6 (Figure S4G). These collective findings suggest 
that the C19MC-LIN28A-MYCN oncogenic circuit acts in concert 
to enhance C19MC oncomiRs and embryonic DNMT3A2/B6 
expression, and thus plays a critical role in promoting or 
maintaining the primitive, malignant epigenetic state that 
characterize ETMRs (Kleinman et al., 2014). 
Hijacked Super-Enhancers Amplify the C19MC-
LIN28A-MYCN Oncogenic Circuit 
As enhancer hijacking by genomic alterations is increasingly 
implicated as an important mechanism in cancers (Lin et al., 
2016; Northcott et al., 2014), we asked whether similar mecha-
nisms may contribute to the C19MC-LIN28A-MYCN oncogenic 
circuit in ETMRs. To investigate these possibilities, we per-
formed and integrated H3K27Ac ChIP-seq (nine tumors) and 
ATAC-seq (seven tumors) with copy-number and RNA-seq 
analyses of primary ETMRs to identify C19MC-, MYCN-, or 
LIN28A-associated enhancers that may be co-opted by genomic 
alterations. In addition, we used C3D (cross cell-type correlation) 
analysis, a tool to predict cis-regulatory interactions, on ETMR 
ATAC-seq data to determine whether these loci may be targeted 
by long-range DNA-DNA interactions. 
Although previous limited RNA-seq studies suggested that high 
C19MC expression was driven by fusion of TTYH1 promoter and 
C19MC gene body, more detailed mapping of RNA-seq data from 
a larger cohort of 22 ETMRs revealed greater complexity to the 
TTYH1-C19MC fusion events (Table S5). Significantly, our 
analyses showed that TTYH1-C19MC fusion breakpoints flanked 
a broad genomic area of 790 kbs (Chr19: 54,142,428– 
54,932,953 bp) enriched for H3K4me1, H3K27me3, and H3K27ac 
marks and DNase I hypersensitive sites, indicating that TTYH1-
C19MC gene fusions may juxtapose distinct putative TTYH1- and 
C19MC-associated enhancers to generate a unique hybrid super-
enhancer (Figure 5A). H3K27Ac ChIP and ATAC-seq analyses of 
ETMRs confirmed that TTYH1-C19MC fusion breakpoints flanked 
a large chromatin accessible region that included a C19MC-
associated enhancer element (Chr19: 54,162,824–54,167,441) 7 
kb upstream of the first C19MC miRNA (miR-512-1) and 20.3 kb 
downstream of the genomic breakpoint (Chr19: 54,142,428), and 
a TTYH1-associated enhancer region (Chr19: 54,925,236–
54,933,011) spanning a 7.7-kb region enriched for multiple 
transcription factor (TF) binding sites, indicating that itwas a super-
enhancer(Filippova etal., 1996; Malik et al., 2014) (Figures 5B and 
S5). Significantly, C3D analysis of ETMR ATAC-seq data revealed 
high probability (r = 0.84; p = 2.63 3 10-10) of direct and specific 
interaction between the C19MC and TTYH1 super-enhancer 
regions (Figure 5C; Table S5) and low probability of DNA-DNA 
interactions between flanking regions Chr19: 54,929,312–
54,930,435 and Chr19: 54,960,066– 54,960,945. Collectively 
these findings point to a unique hybrid super-enhancer, created by 
the TTYH1-C19MC gene fusion (Figure 5D) that spans 32.73 kb, 
as a major driver of high C19MC oncomiR expression in ETMRs. 
Notably, the TTYH1-C19MC hybrid super-enhancer region 
exhibited multiple TF binding sites for MYC and MYC-binding 
partners, MAX and MAZ, further underscoring the importance of 
MYCN and a reciprocal C19MC-MYCN feedforward regulatory 
circuit in ETMRs. 
In contrast, detailed SNP, methylation, and RNA-seq analyses 
did not reveal any focal LIN28A or MYCN genomic alterations in 
ETMRs. C3D analyses of ATAC-seq data predicted no significant 
DNA-DNA interactions targeting the LIN28A promoter in ETMRs. 
However, C3D/ATAC-seq analyses of ETMRs revealed a high 
probability of long-range interactions between the MYCN 
promoter (Chr2: 16,079,544–16,080,544) and five chromatin 
accessible regions on Chr2 (Chr2: 16,124,310– 16,124,602, 
16,154,035–16,154,821, 16,397,969–16,398,207, 16,404,397–
16,405,254, 16,511,152–16,512,136; r > 0.8; p < 1 3 10-10) within 
1.5 Mb upstream of MYCN (Figure 6A; Table S6). ChIP-seq 
analyses of ETMRs showed that all five regions were enriched 
for H3K27Ac marks and spanned binding sites for multiple TFs, 
including CTCF, MYC, and MAX, indicating that they represented 
five distinct enhancers (e1–e5) (Figures 6B and S6A). Notably 
enhancers e1–e5, which correlated with high MYCN expression 
were only evident in ETMRs and hNSCs derived from 11-week-
old fetal brain. These findings suggest that distinct long-range 
interactions between the MYCN promoter and early embryonic 
restricted e1–e5 enhancers contribute to the C19MC-LIN28A-
MYCN oncogenic circuit. 
(H and I) qRT-PCR (H) and western blot analysis (I) of NCCIT andA664 cells treated with LIN28Aorcontrol siRNA, and in stable A664-5miR and vector control 
cell lines. In all cell line experiments, controls are indicated by Ctrl, data are presented as means ± SEM (n = 3); significance was determined by unpaired two-
tailed Student’s t test; *p < 0.05, **p < 0.01; mRNA expression is normalized to actin and tubulin served as western blot loading controls. 
See also Figure S4 and Table S4. 
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Figure 5. A Hybrid Super-Enhancer Is Generated by C19MC-TTYH1 Gene Fusion 
(A) Schematic map of Chr19q13.42 with zoomed view of C19MC (Chr19: 54,144,653–54,271,357) and TTYH1 (Chr19: 54,924,605–54,949,899) relative to UCSC 
hg19 RefSeq annotation and ENCODE tracks. TTYH1-C19MC fusion breakpoints (red inverted arrows) aligned to RNA-seq reads in five representatives primary 
ETMRs are shown in relation to C19MC and TTYH1 promoter, predicted enhancers/super-enhancer (dashed boxes) and gene bodies. 
(B) H3K27Ac ChIP-seq and ATAC-seq tracks from ETMR with (n = 3) and without (n = 2) C19MC amplification, is aligned relative to UCSC gene tracks and 
ENCODE predicted C19MC enhancer (pink) and TTYH1 super-enhancer (orange) regions (dashed boxes). DNA-DNA interactions predicted by ATAC-
seq/C3D analyses of primary ETMR––see (C)––are indicated by curved lines and shown relative to ENCODE ChIP-seq map of transcription factor binding 
sites; MYC/MAZ binding sites are highlighted in red. 
(legend continued on next page) 
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Interestingly, consistent with RNA-seq analyses of ETMRs and 
hNSCs (Figure 6C), a comparison of H3K27Ac enrichment pat-
terns in ETMRs and hNSCs using the ENCODE/Epigenomic 
Roadmap database showed coordinated TTYH1, C19MC, 
LIN28A, MYCN, and DNMT3B6 active enhancer patterns only in 
ETMRs and 11-week-old fetal brain-derived hNSCs, and only 
partial overlap with enhancer patterns in other hNSCs and 
human placenta (Figures 6D and S6B). In contrast to 
DNMT3B6, the DNMT3A2 enhancer was present in a broader 
spectrum of normal and cancer cells. While ETMRs with C19MC 
alterations exhibited both the TTYH1- and C19MC-associated 
enhancers, only TTYH1-associated enhancers were evident in 
ETMRs without C19MC alterations. Taken together, our data 
suggest that unique TTYH1-C19MC hybrid super-enhancers 
and long-range MYCN-enhancer interactions amplify a C19MC-
LIN28A-MYCN oncogenic circuit and drives expression of 
embryonic restricted DNMT3B6 to promote a primitive malignant 
epigenetic state in ETMRs. 
An MYCN-Dependent Core Regulatory Circuit 
Represents a Therapeutic Vulnerability in ETMRs 
Our collective analyses suggest that MYCN dysregulation is a crit-
ical component of the C19MC-driven oncogenic circuit in ETMRs. 
As MYC has been implicated as a master TF, which drives super-
enhancer-dependent regulatory circuits and therapeutic vulnera-
bilities in cancer cells (Schuijers et al., 2018; Zeid et al., 2018), we 
investigated if MYCN may act similarly in ETMRs. We applied the 
ROSE algorithm (Loven et al., 2013; Whyte et al., 2013) on 
H3K27Ac ChIP-seq data from 5 primary tumors and identified 
1,330 super-enhancers, which were then subjected to a core reg-
ulatory circuitry (CRC) analysis to identify key TFs that drive auto-
regulatory loops (Saint-Andre et al., 2016). Of 190 candidate TFs 
(Table S7), 18 emerged as core TFs that mapped to open chro-
matin regions, were highly expressed (fragments per kilobase 
million > 20) in ETMRs, and upregulated in hNSC6-5miR cells (Fig-
ure S7A). These included MYCN and known MYC-binding partner, 
MAZ (Figure 7A). Notably, gene set enrichment analyses of the 
global super-enhancer functional network in ETMRs confirmed a 
predominance of MYCN/MAZ-regulated processes including 
embryonic and CNS development, cellular metabolism, 
differentiation, and survival (Figure 7B; Table S7), which are prom-
inent features of ETMR transcriptional signatures (Li et al., 2009). 
Consistent with these analyses, MYCN and MAZ expression were 
significantly higher than that of MYC and its canonical partner 
MAX, in ETMRs and during early brain development, as indicated 
by BrainSpan data (Figures 7C and 7D). These findings suggest 
that the C19MC-LIN28A oncogenic axis critically drives ETMR cell 
growth primarily via an MYCN/MAZ-mediated core transcriptional 
regulatory circuitry. To investigate this possibility, we treated A664 
parental, A664-vector controls, and A664-5miR 
stable cell lines with JQ1S, an active isomer of JQ1, a bromodo-
main inhibitor that selectively inhibits super-enhancer-associated 
oncogenes such as MYC/MYCN. A664-5miR cells exhibited 
greatest sensitivity to JQ1S, with up to 50% dose-dependent 
reduction in cell viability as compared with parental or vector con-
trol cells (Figures 7E and S7B). Notably, qRT-PCR and western 
blot analyses of cells treated with JQ1S and control inactive 
isomer JQ1R showed significantly greater downregulation of 
C19MC responsive core regulatory circuit effectors MYCN, MAZ, 
LIN28A, DNMT3B6/A2, and BRD2, in JQ1S-treated A664-5miR 
cells as compared with controls (Figures 7F, S7C, and S7D). 
JQ1S treatment in ETMR2373 cells also robustly diminished 
expression of endogenous C19MC miRNAs, LIN28A and 
DNMT3B6, concomitant with increased PARP cleavage, without 
effects on LIN28B, DNMT1, and DNMT3A2 mRNA and protein 
expression (Figures 7G and S7E). These findings suggest that 
convergence of the C19MC-LIN28A and MYCN oncogenic circuits 
critically drive ETMR cell growth and represent a distinct 
therapeutic vulnerability in ETMRs (Figure 8). 
DISCUSSION 
C19MC oncomiRs are upregulated in a spectrum of cancers 
(Huang et al., 2008; Rajaram et al., 2007; Rippe et al., 2010), but 
oncogenic genomic alterations are rare in most cancers. In 
contrast, our analyses revealed that a majority of ETMRs exhibit 
C19MC amplifications/gene fusions and few other recurrent 
CNAs, underscoring C19MC as a specific and major oncogenic 
driver in this disease. Indeed, our cumulative data suggest that 
C19MC is a powerful oncogene that acts to modulate tumor 
suppressors and oncogenes in ETMRs. We show that C19MC 
oncomiRs cooperatively target multiple cell-cycle regulators to 
promote proliferation in hNSC and ETMR cells in a manner similar 
to the orthologous murine miR290–295 cluster that inhibits ESC-
cycle exit by targeting multiple checkpoint genes (Lichner et al., 
2011; Wang et al., 2014). Notably, our data show that C19MC 
acts via inhibition of TTP, an ARE binding tumor suppressor 
protein, to specifically upregulate the onco-genes LIN28A and 
MYCN, but not MYC, which is regulated by TTP in other cancers 
(Kim et al., 2012; Lee et al., 2013). Interestingly, our data show 
that LIN28A also acts as a negative and positive regulator for TTP 
and MYCN, respectively, thus indicating a C19MC-LIN28A-MYCN 
oncogenic circuit that is driven by multiple convergent 
mechanisms in ETMRs. Although ETMRs also have high LIN28B 
expression, our studies show the C19MC/ TTP axis only targets 
LIN28A, indicating that LIN28B is regulated by alternate 
mechanisms. Consistent with our previous studies that implicated 
a LIN28A-let-7 axis in ETMR cell growth (Spence et al., 2014a, 
2014b), we observed very limited expression of let-7 in ETMRs. 
Whether let-7 contributes to LIN28A-MYCN 
(C) Composite correlation matrix of associated open chromatin regions in a 1.5-Mb window around the C19MC enhancer predicted by C3D analysis of ATAC-
seq data from five ETMRs. Absolute correlation is shown proportional to size of colored square, positive and negative correlations are indicated in blue and red, 
respectively. Red box indicates statistically significant areas. All correlations were adjusted for statistical significance (p < 10 3 10_10); blank squares indicate 
insignificant correlations. 
(D) Schema of a representative tumor (ETMR5) showing alignment of TTYH1:C19MC fusion breakpoints (red) with corresponding H3K27Ac ChIP-seq peaks 
and resulting hybrid TTYH1 and C19MC super-enhancer. TTYH1 and C19MC transcriptional start sites are shown in relation to the sequence of a 32.7-kb 
hybrid enhancer. 
See also Figure S5 and Table S5. 
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Figure 6. MYCN Is Targeted by Long-Range Enhancer Interactions on Chr2 
(A) Composite correlation matrix of associated open chromatin regions of the MYCN promoter and distal Chr2 regions predicted by C3D/ATAC-seq analysis of five 
ETMRs. Absolute correlation is shown proportional to size of colored squares, positive and negative correlations are indicated in blue and red, respectively. Red boxes 
mark statistically significant areas. All correlations were adjusted for statistical significance (p < 10 x 10-10); blank squares indicate insignificant correlations. 
(B) Zoomed view of a 439-kb putative MYCN promoter-super-enhancer region mapped using H3K27Ac ChIP and C3D/ATAC-seq analyses of primary ETMRs 
and hNSCs. Arcs indicate predicted interactions of MYCN promoter and five distal enhancers (e1–e5); arc height corresponds to average probability of 
interactions (R value). Composite ATAC-seq maps from five ETMRs are shown in relation to ENCODE DNase I hypersensitivity map. H3K27Ac marks at e1–e5 
in ETMRs and hNSC cell lines are shown relative to ENCODE TF ChIP-seq data; predicted MYC-binding sites are highlighted in red. 
(C) Gene expression heatmap showing MYCN, TTYH1, LIN28A, MYC, and DNMT3A2/3B6 isoform levels in ETMRs (n = 22) and hNSCs (n = 7) determined by 
RNA-seq; *q < 0.05. 
(D) IGV alignment tracks for indicated genes from H3K27Ac ChIP-seq and ATAC-seq analyses of five ETMRs and eight hNSC lines are shown relative to 
ENCODE/ Epigenomic Roadmap H3K27Ac ChIP-seq datasets for placenta, human umbilical vein endothelial cells (HUVEC), and normal human astrocytes 
(NH-A). See also Figure S6 and Table S6. 
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Figure 7. MYCN Drives a Super-Enhancer-Mediated Core Regulatory Circuit in ETMRs 
(A) Diagram of MYCN/MAZ-mediated transcriptional regulatory network and 18 interacting super-enhancer transcription factors (gray circles) identified using 
enhancer-based core regulatory analysis (CRC) of 5 ETMRs. Relationship to MYCN or MAZ nodes are respectively indicated by red or blue lines. 
(B) Cytoscape visualization of pathway enrichment analysis performed on 1,330 super-enhancers identified across 5 ETMRs using ROSE; q < 0.05. 
MYCN/MAZ-regulated biological processes are indicated by red hubs and green lines. 
(C) RNA-seq expression analyses of ETMRs with C19MC amplification (Amp) (n = 13) or gain (Gain) (n = 4), and other PBTs (n = 17). Significance was 
calculated using a t test. *q < 0.05. Data are presented as individual cases with means ± SEM, indicated. 
(D) RNA-seq expression analyses of 0- to 37-week-old fetal brains derived from BrainSpan data. n = 3–45 samples depending on time point. Data are 
presented as means ± SEM. 
(E) Dose-response curves and half maximal inhibitory concentration (IC50) values for A664 vector control (blue) and A664-5miR (red) cell lines 72 h post-
treatment with active isomer JQ1S; **doses with significantly different effects on A664 control and A664-5miR cell lines; **p < 0.01. 
(F) qRT-PCR and western blot analyses of A664 vector control and A664-5miR cell lines treated with active JQ1S or inactive isomer JQ1R for 24 h. 
(legend continued on next page) 
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p27 
p21 
Figure 8. Hijacked Super-Enhancers Amplify 
a C19MC-LIN28A-MYCN Oncogenic Circuit 
to Drive ETMR Transformation 
Schematic model of a C19MC-LIN28A-MYCN 
oncogenic circuit in ETMRs fueled by multiple feed-
forward loops and powerfully amplified by TTYH1-
C19MC- and MYCN-associated super-enhancers 
(SE), an MYCN-driven core transcriptional circuit 
(CRC), and LIN28A-mediated regulation of 
DICER1. C19MC silencing of critical cell-cycle 
proteins p21, p27, and RBL2 acts together with 
MYCN-driven proliferation and LIN28A-mediated 
epigenetic reprogramming to entrap an oncogenic, 
primitive epigenetic cell phenotype in ETMRs. 
Peaks represent H3K27Ac marks. Loops indicate 
DNA-DNA interactions. Solid and dashed lines, 
respectively, indicate functionally validated and 
predicted regulatory relationships. 
promoted but not specifically activated by 
C19MC. Of note, we also identified 
DICER1, a key miRNA biogenesis gene, 
as a LIN28A upregulated target. Taken 
together with our previous observations of 
a C19MC-RBL2-DNMT3B axis (Kleinman 
et al., 2014), these observations indicate 
that C19MC, MYCN, and LIN28A act via 
parallel and synergistic circuits to drive 
and sustain a primitive, malignant epige-
netic program in ETMRs. 
“Locked-In” Primitive Epigenetic, 
Proliferative Cell Phenotype 
regulation in ETMRs, as reported in other cancers (Molenaar et 
al., 2012; Powers et al., 2016), remains to be studied. 
In addition to promoting cell proliferation, our RIP studies sug-
gest that LIN28A plays a major role in ETMR epigenetic program-
ming via direct binding and regulation of mRNAs encoding 
epigenetic regulators including DNMT3A and DNMT3B, which 
have isoform-restricted expression during brain development. 
While DNMT3A2, which functions in genomic imprinting and germ 
cell development (Ma et al., 2015; Nimura et al., 2006), is 
expressed in up to 16-week-old fetal brain, DNMT3B6 expression 
is highest in <8-week-old fetal brain. Interestingly, RNA-seq data 
suggest that DNMT3A2, as well as DNMT3B6, which is the only 
enzymatically active isoform expressed in ETMRs, are almost 
exclusively expressed in ETMRs and not other PBTs, 
underscoring the very distinct and primitive epigenetic features of 
this disease. Both DNMT3A2 and DNMT3B6 are detected in 
ETMRs with and without C19MC copy-number alterations (data 
not shown), indicating that these isoforms may reflect a common 
epigenetic cell state in these tumors that is 
In keeping with early embryonic epige- 
netic features of ETMRs, we observed 
that exogenous C19MC have limited 
transforming activity in postnatal murine 
neural precursors (our unpublished data). 
Consistent with our previous study that linked C19MC 
expression with Sonic hedgehog (SHH) and WNT 
developmental signaling in ETMRs (Li et al., 2009; Picard et 
al., 2012), we observed enrichment of multiple SHH and 
WNT pathway components, including GLI2 and AXIN2, in 
RIP studies indicating that C19MC may act via LIN28A to 
modulate these lineage-determining pathways. Interestingly 
embryonal tumors with histological and transcriptional 
features resembling human ETMRs have been reported by 
concurrent activation of SHH and WNT signaling in murine 
neural precursors (Neumann et al., 2017). However, these 
murine tumors lacked characteristic LIN28A expression 
patterns seen in human tumors, indicating that alternative 
strategies may be needed to model ETMRs. 
Super-enhancers are clusters of enhancers that determine 
cell-type-specific transcriptional signatures by regulating master 
TFs or lineage-associated miRNAs, including miR290–295, 
which define cellular identity and origins (Suzuki et al., 2017; 
Whyte et al., 2013). Super-enhancers have also been 
(G) miRNA qRT-PCR and western blot analyses of ETMR2373 cell lines treated with active JQ1S or inactive isomer JQ1R for 24 h. 
In all cell line experiments, controls are indicated by Ctrl, data are presented as means ± SEM (n = 3); Significance was determined by unpaired two-tailed 
Student’s t test; *p < 0.05; mRNA and miRNA expression are respectively normalized to actin, RNU6B, tubulin served as western blot loading controls. See 
also Figure S7 and Table S7. 
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increasingly implicated in activation of driver oncogenes, and 
they have been shown to confer distinct tumor cell depen-
dencies and sensitivities to drugs that target super-enhancer 
components (Loven et al., 2013). Our studies revealed that su-
per-enhancers co-opted by TTYH1-C19MC gene fusions, and 
long-range MYCN promoter-enhancer interactions, were 
restricted to ETMRs and powerfully amplify a C19MC-LIN28A-
MYCN oncogenic circuit. Notably, our enhancer mapping 
studies suggest that the functional status of TTYH1, C19MC, 
LIN28A, MYCN, and DNMT3B6, which comprise the core com-
ponents of the C19MC-LIN28A-MYCN oncogenic circuit, most 
closely mirrors that of early neural stem cells from —11-week-
old fetal brain. Consistent with a super-enhancer-driven 
C19MC-MYCN dependency in ETMRs, we observed transient 
MYCN knockdown induced growth arrest in A664 cells (data 
not shown), while bromodomain inhibitor JQ1 induced death in 
A664 and A664-5miR cells. Notably, JQ1 treatment 
downregulated only key components of the oncogenic lineage 
circuit including MYCN, LIN28A, DNMT3B6, but not LIN28B, 
DNMT3A2, or DNMT1, which was mirrored by anti-miR-medi-
ated targeting of endogenous C19MC in ETMR2373 cells. 
Thus, we propose that C19MC drives a distinct lineage-associ-
ated dependency and vulnerability in ETMRs. 
Our collective findings in this study highlight ETMR as a devel-
opmental cancer arising in embryonic neural progenitors that is 
driven by hijacked lineage-specific signaling pathways. We identify 
cellular proliferation and embryonic epigenetic programming as 
key features of this disease, which is sustained by a unique potent 
super-enhancer-dependent oncogenic circuit vulnerable to 
bromodomain inhibition. Our data suggest that pharmaco-logic 
agents targeting BET/bromodomains may represent promising 
therapeutics for this recalcitrant orphan cancer. 
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Cufflinks RNAseq assembly suit (v2.2.1) Trapnell et al., 2012 http://cole-trapnell-lab.github.io/cufflinks/ 
Cytoscape Shannon et al., 2003 https://cytoscape.org/ 
 
GraphPad Prism 7.0 GraphPad Software, Inc. https://www.graphpad.com/ 
minfi (v1.20.2) Aryee et al., 2014 http://bioconductor.org/packages/release/bioc/html/minfi.html 
 
PFSK ATCC RRID: CVCL_1642 
HEK293 ATCC RRID: CVCL_0045 
NCCIT ATCC RRID: CVCL_1451 
 
Cutadapt (v1.10) Martinet al., 2011 https://cutadapt.readthedocs.io/en/stable/ 
TopHat (v2.1.0) Kim et al., 2013 https://ccb.jhu.edu/software/tophat/index.shtml 
Integrative Genomics Viewer (v2.3.72) Robinson et al., 2011 http://software.broadinstitute.org/software/igv/home 
Cross Cell-type Correlation based on DNA Mehdi et al., 2018 https://github.com/LupienLabOrganization/C3D 
accessibility (C3D) 
 
corrplot Wei and Simko, 2013 http://CRAN.R-project.org/package=corrplot 
MACS2 Zhang et al., 2008 https://github.com/taoliu/MACS/wiki/Advanced%3A-Call-peaks- 
using-MACS2-subcommands 
ROSE Whyte et al., 2013 http://younglab.wi.mit.edu/super_enhancer_code.html 
CRC Mapper Saint-Andre et al., 2016 https://bitbucket.org/young_computation/crcmapper 
Enrichment Map application Merico et al., 2010 http://baderlab.org/Software/EnrichmentMap 
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CONTACT FOR REAGENT AND RESOURCE SHARING 
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Annie 
Huang (annie.huang@sickkids.ca). 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
Human Tumors and Molecular Analyses 
Tumor samples (90 primary ETMRs and 42 other PBTs) were collected through the Rare Brain Tumor Consortium and Registry 
(http:// www.rarebraintumorconsortium.ca/) with informed consent as per protocols approved by the Hospital for Sick Children. 
Details of molecular analyses performed on tumor samples are listed in Table S1. 
Cell Culture and Transfections 
Daoy (source: male), UW228 (source: female), PFSK (source: male), NCCIT (source: male) and HEK293 (source: female) cells were 
purchased from ATCC and cultured in DMEM or RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS). A664 cells 
(source: female) were derived from a primary cerebral medulloepithelioma (Spence et al., 2014b) and hNSC line hf5205 (source: 
female) was generously provided by Dr. Peter Dirks. ETMR2373 (source: male) cells were generously provided by Drs. Yuchen Du and 
Xiao-Nan Li. A664, hNSC hf5205 and ETMR2373 cells were cultured in NeuroCult media supplemented with 2 mM L-glutamine, 2 
tg/mL Heparin, 75 tg/mL BSA, 10 ng/mL hEGF, 10 ng/mL bFGF, 1x B27 and 1x N2 supplements. All cell lines were incubated at 4% O2 
in a humidity-controlled environment (37°C, 5% CO2). All cells were utilized before passage 10 and treated in exponential growth phase 
at 70% confluency. hNSC 3-10 were obtained from various sources as described in Table S1. Transient transfection were performed 
with plasmid DNA or scramble/LIN28A-specific siRNA (Dharmacon, Cat#D-001810-01/J-018411-09) using Fugene (Promega, 
Cat#E2691) or Lipofectamine 2000 (Life Technologies, Cat#11668019) as per the manufacturer’s protocols. 
METHOD DETAILS 
Expression Constructs and Stable Cell Lines 
5miR expression plasmid was generated by designing a cluster of 5 (miR520g, miR519a, miR517c, miR517a and miR512-3p) miRNA 
precursor stem loop structures in a pcDH-CMV-MCS-EF1-copGFP vector and synthesized by System Biosciences. LIN28A expression 
construct (Yu et al., 2007) was obtained from Addgene (Cat#16350). Both constructs were sub-cloned into pcDH-CMV-EF1-
copGFP/RFP (System Biosciences, Cat#CD511B-1/CD512B-1). TTP expression construct was obtained from SIDNET (The Hospital 
for Sick Children) and cloned into a pcDNA3.1/nFLAG expression construct. Lentivirus was generated and used for stable cell lines 
generation as per the Hospital for Sick Children safety guidelines. Expression of C19MC miRNAs and LIN28A were confirmed with 
qRT-PCR and/or western blotting. 
Cell Growth, Cell Cycle Assay and JQ1 Treatment 
Between 500-2000 cells/well were seeded in triplicate in 96-well plates in 100 tl of culture media and incubated overnight. Cell 
growth was evaluated daily for a period of 5-7 days upon addition of 20 tl/well of MTS reagent (Promega, Cat#G3582) and viable 
cell numbers were determined at absorbance 575 nm using Versamax microplate reader (Molecular Devices). For cell cycle 
analysis, 1E6 cells were fixed with ice-cold 70% ethanol, washed and treated with 100 tg/mL RNaseA, 50 tg/mL propidium iodide 
and 0.1% NP-40. Cells were filtered through 85-tm Nitex mesh and followed by fluorescence activated cell sorting (FACS) 
analysis. The proportion of cell in different cell cycle phases was determined using FlowJo software (Tree Star). 
To determine IC50 for JQ1 treatments, A664, A664-pcDH and A664-5miR cells were seeded at 4,000 cells/well in a 96 well 
plate, allowed to adhere overnight and treated with JQ1 (generously provided by Dr. Dalia Barsyte-Lovejoy, Structural Genomics 
Consortium, University of Toronto) the following day. Cell viability was assessed using Alamar Blue at 72 hr post-treatment using 
an 8-point dose curve with drug doses from 0.1 nM-10 tM. Viable cell percentage for each concentration was determined relative 
to DMSO control. IC50 values were calculated using GraphPad Prism 7.0. A664 cells were treated with 570 nM JQ1R and JQ1S 
for cell growth assays or harvested 24 hr post-treatment for biochemical analysis. All cellular assays were performed in triplicate. 
RNA Extraction and qRT-PCR Analysis 
RNA was harvested via Trizol extraction as per manufacturer’s instructions. cDNAs were synthesized from high quality RNA using 
High Capacity cDNA Reverse Transcriptase Kit (Applied Biosystem, Cat#4368814) and qRT-PCR analyses were performed using 
SYBR Select (Thermo Scientific, Cat#4472908) with custom designed PCR primers to amplify invariant exons or exon-exon 
junctions (For primer sequences, see Table S8). mRNA expression was calculated using the 2-DDCT method; genes with Ct values 
R30 were excluded from analysis. Data was normalized to actin expression. 
microRNA qRT-PCR was performed using 10 ng of RNA reversed transcribed using microRNA-specific stem-loop reverse tran-
scription primers and TaqMan microRNA Reverse Transcription Kit (Thermo Fisher Scientific, Cat#4366596). miRNA qRT-PCR 
was performed using TaqMan Universal PCR Master Mix no AmpErase UNG (Thermo Fisher Scientific, Cat#4324018) and 
individual microRNA PCR probes. Data was normalized to RNU6B expression. All qRT-PCR analyses were performed n=3. 
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Immuno-Histochemical (IHC) and Western Blotting Analysis 
For IHC studies, a heat-induced antigen retrieval process was used, followed by blocking of endogenous peroxidase and biotin. 
Primary antibodies against p21 (Cell signaling, Cat#2947), p27 (BD Biosciences, Cat#610242) and RBL2 (Sigma Aldrich, 
Cat#HPA019703) were used. Antibody reactivity was visualized using VectaStain ABC detection kit (Vector Laboratories, Cat#PK-
4000). For western blot analyses, whole cell lysates were prepared using cytosol lysis buffer and probed with various antibodies 
using standard protocols. (For antibodies, see Key Resources Table). Immunoreactivity was detected using secondary anti-
species horseradish peroxidase–conjugated antibodies (GE Healthcare, #NAV934/931) and Chemi-luminescence Reagent Plus 
(PerkinElmer, Cat#NEL103001EA). 
miRNA In Situ Hybridization Analysis 
miRNA in situ hybridization (ISH) was performed using Alexa 488 (Thermo Fisher, Cat# A20181) coupled miR520g or scrambled 
probes (Qiagen) on sequentially sectioned formalin fixed paraffin embedded primary ETMR using miRCURY LNA miRNA ISH 
Optimization Kit (Qiagen, Cat#339451). Signals were amplified using Tyramide Signal Amplification kit (Thermo Scientific, 
Cat#B40953). Fluorescence was detected using the Pannoramic 250 Flash series digital scanner. To compare miRNA amplified 
tumor cells with protein levels of p21, p27 and RBL2, we performed IHC analysis on sequentially sectioned tumors of the same 
ETMR and located the same geographical region on the tumor for all analyses. 
Luciferase Reporter Assays 
To assess direct effects of 5miR on target genes, 3’UTR constructs of p21, p27 and TTP from corresponding full lengths genes 
(SPARC, Hospital for Sick Children; Canada) were sub-cloned into a pmirGLO Dual-Luciferase miRNA target expression vector 
(Promega, Cat#E1330). C19MC binding sites were identified using miRNA target prediction algorithms (Targetscan, miRanda and 
DIANA – see Table S2) and seed sequences mutated using QuiKChange Site directed mutagenesis kit (Stratagene, Cat#200524). 
For luciferase assays, stable UW228-pcDH/miR520g/5miR cells were seeded at 0.3E5/well in triplicate in a 12-well plate and 
trans-fected with empty pmiRGLO, wild-type, mutated target gene 3’UTR or a control miR520g complementary (520-t) vector. 
Cells were harvested 48 hours post-transfection using Dual-Luciferase Reporter Assay System (Promega, Cat#E1910) and 
luciferase activity measured using the Lumat LB 9507 tube luminometer. Luciferase activity was normalized to empty pmiRGLO 
vector and Renilla. All assays were performed n=3. 
Identification of C19MC Gene Targets 
To identify which of the 179 downregulated cell cycle genes may be targeted by the 5 major classes of C19MC miRNA families 
(miR-520, 519, 517a/c and 512), we utilized three distinct miRNA target predictions algorithms including TargetScan, miRanda and 
DIANA. Our strict criteria included a) whether the 3’UTR of these genes contained R2 C19MC binding sites, b) whether the same 
binding site locations were conserved across all three algorithms and c) whether the sites were evolutionarily conserved. Based on 
these criteria, 11/179 genes emerged as C19MC candidate targets. H3K27Ac and ATACseq data were used to validate the 
functional status of the 11 candidate targets in primary ETMR, which revealed only 5 genes (p21, p27, RBL2, CCND2 and AHR) that 
exhibited active enhancers and open chromatin, indicating these genes were transcriptionally active in ETMRs. 
RNA Binding Protein Predictions 
The RNA Binding Protein Data Base software (http://rbpdb.ccbr.utoronto.ca/) (Cook et al., 2011) was used to predict RNA binding 
protein targeted to the 3’UTR of LIN28A, MYCN, LIN28B and MYC. 
LIN28A RNA-Immunoprecipitation (RIP) and Sequencing 
LIN28A RIP was performed using RNA-Chip IT (Active Motif, Cat#53024) using previously described methods (Cho et al., 2012; Wilbert 
et al., 2012). Briefly, formaldehyde cross-linked chromatin from 1E6 A664 cells was fragmented via water bath sonication to 100-1000 
bp fragments. Samples were treated with DNase I and RIP performed using 4 mg LIN28A antibody (Abcam, Cat#ab46020) or normal 
rabbit IgG (Santa Cruz Biotechnology, Cat#sc2027) and rotated overnight at 4°C. Chromatin was de-crosslinked using Proteinase K and 
RNA isolated via Trizol extraction followed by DNase I treatment. DNA libraries were prepared using Clontech Ultralow kit and 
sequenced by paired-end Illumina HiSeq 2500 sequencing at the Donnelly Sequencing Centre (University of Toronto). Alignment and 
peaks were called using MACS2 software (v2.1.0.20140616) (Zhang et al., 2008). Gene Set Enrichment Analysis (Mootha et al., 2003) 
was performed to identify transcriptional networks and visualized using Cytoscape (Shannon et al., 2003). 
Methylation Analysis 
DNA from frozen tissue and formalin-fixed, paraffin-embedded (FFPE) materials were analyzed with the Illumina Infinium Human 
Methylation 450k and MethylationEPIC arrays according to manufacturer’s instructions and published methods (Torchia et al., 
2016; Triche et al., 2013). To integrate both array platforms, only probes that are found in the 450k array were retained. 
Background correction and dye-bias normalization were performed using the normal-exponential out-of-band method from the R 
package minfi (v1.20.2) (Aryee et al., 2014). CpG sites with detection p value <0.01 were retained for analysis and only samples 
with <5% failed probes were retained. The most variable methylated probes ranging from 5,000-15,000 (s.d.>0.3) were selected 
for all downstream analysis. All analyses were performed in the R environment (3.3.3) except when noted. 
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Unsupervised Analysis of ETMR with Other Paediatric Brain Tumor 
For unsupervised analyses of ETMR and other PBTs, raw idats or normalized beta matrix values of methylation data for medulloblas-
toma (Jones et al., 2012), atypical teratoid/rhabdoid tumor (ATRT) (Johann et al., 2016; Torchia et al., 2016), neuroblastoma (Gomez et 
al., 2015), pilocytic astrocytoma (Lambert et al., 2013), ependymoma (Mack et al., 2014; Sturm et al., 2016), high grade glioma (Sturm 
et al., 2012, 2016), pineoblastoma (Sturm et al., 2016) were downloaded from GEO and combined with in-house samples in the pipeline 
described above. Principal component analysis (PCA) was performed using R package stats (v3.3.3) and the top 50 principle 
component used for tSNE analysis with the Rtsne package (v0.13). 5-50 perplexity were tested to find the optimal settings. Other non-
default settings: pca=F, max_iter=5000, theta=0. Each of the aforementioned tumor group form distinct entities with no batch effect by 
material type and processing date was observed with distinct clustering of samples according to tumor subtype. 
Genome Wide Copy Number Alteration Analysis with Methylation and SNP Arrays 
Genome-wide copy number analyses were performed using SNP (n=33) and methylation array data (n=77). For SNP array 
analyses, the Illumina OmniQuad array platform was used. Probe fluorescence intensity normalization and transformation was 
performed using Illumina Genome Studio (v. 2011.1 Genotyping Module 1.9.4) and represented as LogR ratio (Log2[Rexperiment/Rcontrolset]) 
and B-allele frequency (BAF) using hg19 human reference genome. ASCAT (Allele Specific Copy Number Analysis of Tumors) was 
performed to assess tumor purity and ploidy using its control-free analysis function at default parameters. Methylation array data 
was analysed using the R package conumee for the 450k array and EPIC array (v 1.2.0 and 1.8.0 respectively) using default 
settings. For both methylation and SNP array data, tumor probe level LogR and segmented profiles were visualize using the R 
package Gviz (version 1.18.2). Recurrent focal and arm-level structural alteration was analyzed using GISTIC2 (v03172017). At 
least half of the chromosome arm must be affected to be considered as a broad event for arm-level structural alteration analysis. For 
focal alterations, -0.3 and 0.3 deletion and gain threshold respectively to identify driver events with the HLA region Chr6:28477797-
33448354 excluded. For both type of analysis, significant alterations were evaluated based on Benjamin-Hochberg false discovery 
rate corrected p values for each marker from comparing the score at each locus to background score generated by random 
permutation of marker location with q % 0.01. 
Normalized and log2-transformed copy number measurements were imported and analysed using CopyNumber package 
pipeline (Nilsen et al., 2012) to identify segments with similar copy number. Binned segmentation results of conumee output from 
methylation arrays from all primary ETMR (N=77) were used to generate a composite copy number plot. Average Log2 levels were 
calculated across overlapping segments with noise removal from HLA region and end of chromosome arm using an in-house 
script. The results were plotted using Circos (v0.69). 
Processing of miRNA Nanostring Data 
Total RNA (100ng) from 21 ETMRs with C19MC structural alterations and 28 other PBTs was prepared with nCounter miRNA 
Sample Prep Kit according to standard protocol. miRNA expression profiling was conducted with human v1, v2, or v3 miRNA 
panel on nCounter miRNA expression platform (NanoString Technologies, Seattle, WA) according to manufacturer’s protocol. 
Signal normalization was done using nSolver Analysis and batch corrected using ComBat (Johnson et al., 2007). 565 miRNAs 
overlapped between all three versions and was used for further analyses. Fold change and supervised t-test with FDR correction 
was calculated between the ETMRs and other PBTs. 
RNAseq Analyses and Fusion Calling 
RNAseq of tumor and cell lines were performed at the Princess Margaret Genomics Centre (Toronto, Ontario). RNA was prepared 
using either the IlluminaTruSeq RNA sample preparation kit for poly-adenylated mRNA or Illumina RiboZero Stranded library 
preparation kit for total RNA with an average of 97.64 million and 92.13 million paired-end reads per sample respectively. Adapter 
sequences were trimmed using Cutadapt (v 1.10) and aligned to human reference genome hg19 using TopHat (v2.1.0). Gene 
expression values were represented as FPKM values generated from RNAseq alignments using cuffquant and cuffnorm programs 
within the Cufflinks RNAseq assembly suit (v2.2.1) (Trapnell et al., 2012) with geometric library normalization. 
TTYH1-C19MC gene fusion break points were assessed based on concordance of and SNP array/Methylation array copy number 
analysis. RNAseq fusions breakpoints were called using TopHat-Fusion (v2.1.0). Paired-end reads were aligned to a GRCh19 refer-
ence genome using the following parameters specifically for finding fusion transcripts: –fusion-anchor-length 15 –fusion-min-dist 
10000 –segment-length 50 –mate-inner-dist 0 –mate-std-dev 80. False positive from TopHat-Fusion were further assessed using 
TopHat-fusion-post by aligning the sequences flanking fusion junctions against BLAST (Basic Local Alignment Search Tool) data-
bases (human genomic, other genomic and nt) and also manual inspection with Integrative Genomics Viewer (IGV) (v2.3.72). 
Methylation and RNAseq Public Data 
Additional methylation (GSE49377, GSE54719, GSE70460, GSE75153, GSE73801, EGAS00001000506) and RNAseq 
(SRP032476) data were downloaded from public resources. 
H3K27Ac ChIPseq Sample Preparation and Analysis 
Snap-frozen primary tissues were prepared for H3K27Ac ChIPseq analyses according to previously published methods (Mack et al., 
2018). Briefly, formaldehyde cross-linked chromatin from 1E6 cells or 5 mg of snap frozen tumor samples were fragmented via water 
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bath sonication to 200 bp fragments. Chromatin immunoprecipitation (ChIP) was performed using 5 pg of H3K27Ac antibody 
(#39133 Active Motif; CA, USA), which was pre-incubated for 6 hours with Dynabeads A and G (Invitrogen; CA, USA) and rotated 
overnight at 4°C. Antibody-free chromatin was retained as input control. Chromatin was de-crosslinked using 1% SDS and 0.1 M 
NaHCO3 and DNA was purified using QIAGEN QIAquick PCR purification kit (Cat # 28104), and quantified using PICO green. 
DNA libraries were prepared using NEB Next ChIPseq Illumina Sequencing library preparation kit. Samples were barcoded using 
NEB Next Barcodes (New England Biolabs; ON, Canada) and pooled in equimolar amounts. Sequencing was performed using 
pair-end 50 bp reads on the Illumina HiSeq 2000 sequencing (Beckman Coulter; MA, USA). Peaks were called using the MACS2 
software (v2.1.0.20140616) (Zhang et al., 2008). 
ATACseq Sample Preparation and Analysis 
Snap-frozen primary tissue was prepared for ATACseq according to previously published methods with minor modifications (Buen-
rostro et al., 2015). Briefly, nuclei were prepared from 50,000 cells by spinning at 600 x g for 10 min, followed by a wash using 50 pl 
PBS buffer, and further centrifugation at 600 x g for 5 min. Cells were lysed using cold lysis buffer (10 mM Tris -HCl, pH 7.4, 10 mM 
NaCl, 3 mM MgCl2, 0.1%), and subsequently centrifuged for 10 min at 600 x g at 4°C. The supernatant was removed and pellet re-
suspended in 50 pl of transposase mix (25 pl of 2xTD Buffer, 2.5 pl of transposase (TD enzyme; Illumina), 22.5 pl of water) for 30 min 
at 37°C. Next, library amplification was performed using the NEBnext High Fidelity 2xPCR Master Mix (Cat#M0541S) according to 
previously published PCR conditions (Buenrostro et al., 2015). PCR reactions were purified using QIAGEN miniElute kit, and a 
following size selection step was performed using LabChip (Cat#760601). ATACseq library preparations were sequenced using 
single-end 50 bp reads on the Illumina HiSeq 2000 platform. Raw reads were adapter-trimmed using Trim Galore (v0.2.5) and aligned 
to the genome with Bowtie (v1.0.1) with the m1 option enabled to allow for only uniquely aligned high-quality reads. Peaks were called 
using the MACS2 software (v2.1.0.20140616) (Zhang et al., 2008) with the options –q 0.05 to retain significant peaks, –shiftsize 50 to 
account for the transposase fingerprint, and otherwise default parameters were used. 
Mapping Long Range Enhancer Interaction Using C3D 
We applied Cross Cell-type Correlation in DNase I hypersensitivity (C3D) analysis, which calculates correlations between open regions 
of chromatin based on DNase I hypersensitivity signals or ATAC sequencing (Mehdi et al., 2018), to ATACseq data from 5 ETMRs to 
confirm presence of the TTYH1-C19MC gene fusions and discover long range MYCN promoter-enhancer interactions using prior 
published methods. C3D analyses performed with the MYCN promoter (Chr2:16,079,544-16,080,544) as an anchor (R >0.4, p<10-10) 
identified 173 interacting regions (R>0.4, p<10-10) on chromosome 2 that mapped at least 1 Kb outside of gene bodies in at least 1/5 
ETMRs; 13 interacting regions which were identified in 4/5 ETMRs were further narrowed down to 5 candidate enhancer regions based 
on overlap with H3K27Ac ChIPseq Broadpeaks (p<0.01) in 5/5 (Table S6). Further analyses showed that the 5 open enhancer regions, 
which mapped in a gene desert upstream of MYCN promoter, only correlated with expression of MYCN while GACAT3, the only other 
gene residing in the region of predicted DNA looping, is not expressed in ETMRs (average FPKM = 0.21198). 
Additionally, results from a separate C3D analysis performed using ATACseq data from 2 ATRT primary tumors and MYCN pro-
moter as an anchor revealed 4 interaction regions (R>0.4, p<10-10) that mapped to chromosome 2 in at least 1/2 tumors. 1 region 
(Chr2:2617107-2617587) overlapped with H3K27Ac ChIPseq Broadpeaks (p<0.01) to reveal a putative long-range enhancer. C3D 
analysis on ETMRs using the LIN28A promoter (Chr1:26,737,148-26,738,148) as an anchor only revealed 1 possible interaction in 
1/5 ETMR primary tumors. C3D analysis of the C19MC enhancer (Chr19:54164387-54168379) revealed 192 DNA-DNA 
interactions within a 1.5Mb window. Subsequent analysis focused on statistically significant interactions (q<0.05). All correlations 
were tested for statistical significance and adjusted for multiple testing (FDR) within the 1.5 Mb window. Correlation matrices were 
generated using the corrplot R package (Wei and Simko, 2013). 
Core Regulatory Circuitry (CRC) Analyses 
H3K27Ac ChIPseq peaks were calculated for 5 ETMR tumors using the MACS2 algorithm (Model-Based Analysis of ChIPseq). A q-
value threshold of enrichment of 1 x 10-5 was used for all data sets. Super-enhancers were identified using the ROSE (Rank Ordering 
of Super-Enhancers) algorithm (Whyte et al., 2013) based on the H3K27ac ChIPseq signal with the default parameters. MACS2, 
ROSE output and RNAseq values (FPKM >1) were used to identify the core master TFs using CRC mapper (Saint-Andre et al., 
2016). The algorithm identified 190 putative master TFs (Table S7), which were narrowed down based on chromatin accessibility 
using ATACseq data (q value <0.05), high RNA expression (FPKM >20) and upregulation in hNSC6-5mir vs. control to 18 TFs (Table 
S7). Master TFs were further narrowed down on positive correlation (R-value) between RNAseq values of each putative TF correlated 
with average C19MC miRNA expression using Nanostring data. The TF list was then overlapped with genes that were upregulated in 
hNSC6-5miR vs hNSC6-pcDH. Finally, we overlapped TF list with genes that were upregulated in A664-5miR compared to A664-
pcDH and also significantly up-regulated in ETMRs compared to other PBTs using RNAseq data (q<0.05). 
Super-Enhancer Pathway Analysis 
ROSE algorithm identified 1330 super-enhancers that were present in at least 1/5 tumors. The output was annotated using a 
custom script that assigned super-enhancer regions to the nearest highest expressed gene within a 100 Kb window. List of super-
enhancers were input into gProfiler (Reimand et al., 2016) and pathways were selected using FDR<0.01 and visualized using the 
Enrichment Map application (Merico et al., 2010) for Cytoscape (Shannon et al., 2003). 
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DATA AND SOFTWARE AVAILABILITY 
The accession number for the ETMR RNAseq, H3K27Ac ChIPseq, ATACseq, Nanostring, methylation, SNP genotyping array and 
LIN28A RIPseq data reported in this paper is EGA: EGAS00001003437 and can be reached through this link: https://www.ebi.ac. 
uk/ega/studies/EGAS00001003437. 
QUANTIFICATION AND STATISTICAL ANALYSIS 
Kruskal-Wallis test was used to assess significance of gene expressions between ETMR and other PBTs, as well as between 
C19MC amplified and gained tumors. A two-tailed student t-test was used to calculate significance for all cellular and biochemical 
assays. A p value of <0.05 was regarded as significant for all analyses. Statistical significance and number of replicates indicated 
in figure legends. Error bars shown as Standard Error of Mean (SEM). Benjamin-Hochberg correction method was used to 
calculate q values from H3K37Ac-ChIPseq and ATACseq peaks relative to input control sample. All analyses were conducted in 
the R statistical environment (v2.15.2) or with the GraphPad Prism 7.0 software. 
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